|
|
Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer's disease
Sources News Release
http://www.sources.com/Releases/NR1117.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 11/01/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
Abstract: Meets major clinical development milestone for lead compound
December 21, 2010
Hoboken, NJ – December 21, 2010 - Anavex Life Sciences Corp. (“Anavex”, AVXL:OB) announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.
"This regulatory filing marks an important milestone in the clinical devel...
To read the full release go to http://www.sources.com/Releases/NR1117.htm
Topics
|
AlterLinks
c/o Sources
© 2023.
|
|
|
|
